» Articles » PMID: 35508789

Ribosomal Proteins Induce Stem Cell-like Characteristics in Glioma Cells As an "extra-ribosomal Function"

Overview
Date 2022 May 4
PMID 35508789
Authors
Affiliations
Soon will be listed here.
Abstract

The characteristic features of plasticity and heterogeneity in glioblastoma (GB) cells cause therapeutic difficulties. GB cells are exposed to various stimuli from the tumor microenvironment and acquire the potential to resist chemoradiotherapy. To investigate how GB cells acquire stem cell-like phenotypes, we focused on ribosomal proteins, because ribosome incorporation has been reported to induce stem cell-like phenotypes in somatic cells. Furthermore, dysregulation of ribosome biogenesis has been reported in several types of cancer. We focused on ribosomal protein S6, which promotes sphere-forming ability and stem cell marker expression in GB cells. We expect that investigation of dysregulation of ribosome biogenesis and extra-ribosomal function in GB will provide new insights about the plasticity, heterogeneity, and therapeutic resistance of GB cells, which can potentially lead to revolutionary therapeutic strategies.

Citing Articles

Essential genes analysis reveals small ribosomal subunit protein eS28 may be a prognostic factor and potential vulnerability in osteosarcoma.

Liang C, Zhou J, Wang Y, Sun Y, Zhou J, Shao L J Bone Oncol. 2024; 44:100517.

PMID: 38204480 PMC: 10776981. DOI: 10.1016/j.jbo.2023.100517.


Sabotaging the protein factory to overcome glioma stem cell resistance.

Haase S, Lowenstein P, Castro M Neuro Oncol. 2023; 25(8):1441-1442.

PMID: 37177889 PMC: 10398797. DOI: 10.1093/neuonc/noad090.


Ribosomes and Ribosomal Proteins Promote Plasticity and Stemness Induction in Glioma Cells via Reprogramming.

Hide T, Shibahara I, Inukai M, Shigeeda R, Kumabe T Cells. 2022; 11(14).

PMID: 35883585 PMC: 9323835. DOI: 10.3390/cells11142142.

References
1.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

2.
Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

3.
Singh S, Clarke I, Hide T, Dirks P . Cancer stem cells in nervous system tumors. Oncogene. 2004; 23(43):7267-73. DOI: 10.1038/sj.onc.1207946. View

4.
Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

5.
Andersen B, Faust Akl C, Wheeler M, Chiocca E, Reardon D, Quintana F . Glial and myeloid heterogeneity in the brain tumour microenvironment. Nat Rev Cancer. 2021; 21(12):786-802. PMC: 8616823. DOI: 10.1038/s41568-021-00397-3. View